On November 10, DR10624 fatty liver disease phase II clinical study data independently developed by Zhejiang Daoer Biotechnology Co., Ltd., a subsidiary of Huadong Pharmaceutical, was revealed for the first time. The results showed that all dose groups of DR10624 showed significant reduction in LFC, and the effect was rapid. MASLD/MASH patients can observe a significant decrease in liver fat content only 6 weeks after receiving DR10624 treatment. At week 12, the relative decrease in LFC in each dose group of DR10624 compared to the baseline was greater than that of the placebo group. The difference was statistically significant.
Zhitongcaijing · 2d ago
Share
Listen to the news
On November 10, DR10624 fatty liver disease phase II clinical study data independently developed by Zhejiang Daoer Biotechnology Co., Ltd., a subsidiary of Huadong Pharmaceutical, was revealed for the first time. The results showed that all dose groups of DR10624 showed significant reduction in LFC, and the effect was rapid. MASLD/MASH patients can observe a significant decrease in liver fat content only 6 weeks after receiving DR10624 treatment. At week 12, the relative decrease in LFC in each dose group of DR10624 compared to the baseline was greater than that of the placebo group. The difference was statistically significant.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending